A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age

Project: Other project

Project Details

StatusActive
Effective start/end date10/19/2110/18/26

Funding

  • Merck Sharp & Dohme Corporation: $13,653.85